Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by retiredcfon Mar 23, 2017 7:44am
233 Views
Post# 26018698

Top Pick

Top PickFirst stock in the clip. GLTA

https://www.bnn.ca/video/stephen-takacsy-top-picks~1083785

NAPEC (NPC.TO) – New position purchased late in 2016 at under $1 during new equity issue

Quebec-based leading provider of construction and maintenance services to electrical and gas utilities

Nearly 80 per cent of revenues are now from the U.S.

New management team has cleaned-up corporate structure and has a new strategic plan to aggressively grow core business and improve margins

Large capex programs underway in the U.S. to replace aging gas and electrical distribution systems

Opportunities could grow with further boost in U.S. infrastructure spending

Recently completed what should prove to be a very accretive acquisition in the NYC area. Pro-forma revenues of $400 million and backlog of nearly $800 million

Stock is very cheap at under 6x forward EBITDA versus U.S. comparable companies which have rallied since U.S. elections

Target price $2.50 within a few years.
 

2017-03-22 TOP PICK Stephen Takacsy, B. Eng, MBA
 
One of the leading construction and maintenance services to electrical and gas utilities. Over 80% of revenues come from the US. They will definitely benefit from more infrastructure spending, but have a huge backlog of work right now. The gas and electrical transmission lines in the US are being replaced and expanded. Made a couple of very accretive acquisitions which should start kicking in soon. Very cheap, trading at under 6X EBITDA. (Analysts’ price target is $1.38.)
 
Login to show your approval   Login to show your disapproval / Be the first to comment
Price:
$1.050
Subject:
CANADIAN
Bias:
UNKNOWN
Owned:

 

Yes
 
<< Previous
Bullboard Posts
Next >>